External broker reports(aggregated public sources), Motilal Oswal Financial Services Limited

Motilal Oswal

Motilal Oswal Financial Services Limited is an Indian diversified financial services firm offering a range of financial products and services. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only.  Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Motilal Oswal Financial Services Limited

Motilal Oswal Financial Services Limited is an Indian diversified financial services firm offering a range of financial products and services. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

<ul><li>Motilal Oswal's research report onLupin Lupin (LPC) delivered in-line operational performance in 4QFY24. LPC ended FY24 on a strong note, with INR198b in sales (up 19% YoY), EBITDA margin of 18% (up 750bp YoY) and PAT of INR19b (vs. INR4b YoY).</li><li>LPC continues to implement efforts toward building a complex product pipeline in inhalation, injectables and ophthalmic.</li><li>We raise our earnings estimates by 6% each for FY25/FY26, factoring in a) limited competition product launches in the US generics segment, b) industry outperformance in the DF segment, and c) a scale-up in the diagnostic business. </li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Motilal Oswal's research report onLupin Lupin (LPC) delivered in-line operational performance in 4QFY24. LPC ended FY24 on a strong note, with INR198b in sales (up 19% YoY), EBITDA margin of 18% (up 750bp YoY) and PAT of INR19b (vs. INR4b YoY).LPC continues to implement efforts toward building a complex product pipeline in inhalation, injectables and ophthalmic.We raise our earnings estimates by 6% each for FY25/FY26, factoring in a) limited competition product launches in the US generics segment, b) industry outperformance in the DF segment, and c) a scale-up in the diagnostic business. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Lupin - Niche Product Drives Earnings Growth

Lupin Ltd

Lupin - Niche Product Drives Earnings Growth